UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 47

Sortiert nach

Preclinical characterization of abemaciclib in hormone receptor positive breast cancer

Oncotarget, 2017-09, Vol.8 (41), p.69493-69507

2017

Link zum Volltext

Verfügbarkeit prüfen

Assay Establishment and Validation of a High-Throughput Screening Platform for Three-Dimensional Patient-Derived Colon Cancer Organoid Cultures

Journal of biomolecular screening, 2016-10, Vol.21 (9), p.931-941

2016

Link zum Volltext

Verfügbarkeit prüfen

TPX2 overexpression promotes sensitivity to dasatinib in breast cancer by activating YAP transcriptional signaling

Molecular oncology, 2024-06, Vol.18 (6), p.1531-1551

2024

Link zum Volltext

Verfügbarkeit prüfen

Cyclin dependent kinase (CDK) inhibitors as anticancer drugs

Bioorganic & medicinal chemistry letters, 2015-09, Vol.25 (17), p.3420-3435

2015

Link zum Volltext

Verfügbarkeit prüfen

Phenotypic Screening Approaches to Develop Aurora Kinase Inhibitors: Drug Discovery Perspectives

Frontiers in oncology, 2016-01, Vol.5, p.299-299

2016

Link zum Volltext

Verfügbarkeit prüfen

Preclinical characterization of the CDK4/6 inhibitor LY2835219: in-vivo cell cycle-dependent/independent anti-tumor activities alone/in combination with gemcitabine

Investigational new drugs, 2014-10, Vol.32 (5), p.825-837

2014

Link zum Volltext

Verfügbarkeit prüfen

Multiparametric cell-based assay for the evaluation of transcription inhibition by high-content imaging

Journal of biomolecular screening, 2013-06, Vol.18 (5), p.556-566

2013

Link zum Volltext

Verfügbarkeit prüfen

Design, synthesis and validation of a new Crimped Head-Piece for DNA-Encoded libraries generation

Bioorganic & medicinal chemistry, 2024-02, Vol.99, p.117596-117596, Article 117596

2024

Link zum Volltext

Verfügbarkeit prüfen

Aurora A-Selective Inhibitor LY3295668 Leads to Dominant Mitotic Arrest, Apoptosis in Cancer Cells, and Shows Potent Preclinical Antitumor Efficacy

Molecular cancer therapeutics, 2019-12, Vol.18 (12), p.2207-2219

2019

Link zum Volltext

Verfügbarkeit prüfen

Crystal structure of active CDK4-cyclin D and mechanistic basis for abemaciclib efficacy

NPJ breast cancer, 2022-11, Vol.8 (1), p.126-126, Article 126

2022

Link zum Volltext

Verfügbarkeit prüfen

The interaction of p62 with RIP links the atypical PKCs to NF-κB activation

The EMBO journal, 1999-06, Vol.18 (11), p.3044-3053

1999

Link zum Volltext

Verfügbarkeit prüfen

Activation of IκB Kinase β by Protein Kinase C Isoforms

Molecular and Cellular Biology, 1999-03, Vol.19 (3), p.2180-2188

1999

Link zum Volltext

Verfügbarkeit prüfen

Author Correction: Crystal structure of active CDK4-cyclin D and mechanistic basis for abemaciclib efficacy

NPJ breast cancer, 2022-12, Vol.8 (1), p.133-133, Article 133

2022

Link zum Volltext

Verfügbarkeit prüfen

Cyclin dependent kinase (CDK) inhibitors as anticancer drugs: Recent advances (2015–2019)

Bioorganic & medicinal chemistry letters, 2019-10, Vol.29 (20), p.126637-126637, Article 126637

2019

Link zum Volltext

Verfügbarkeit prüfen

Abemaciclib, a CDK4 and 6 inhibitor with unique pharmacological properties for breast cancer therapy

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.e12506-e12506

2021

Link zum Volltext

Verfügbarkeit prüfen

Abstract 1236: Preclinical characterization of LY3484356, a novel, potent and orally bioavailable selective estrogen receptor degrader (SERD)

Cancer research (Chicago, Ill.), 2021-07, Vol.81 (13_Supplement), p.1236-1236

2021

Link zum Volltext

Verfügbarkeit prüfen

Splicing Regulation at the Second Catalytic Step by Sex-lethal Involves 3′ Splice Site Recognition by SPF45

Cell, 2002-05, Vol.109 (3), p.285-296

2002

Link zum Volltext

Verfügbarkeit prüfen

Abstract 1852: Combination of the CDK4/6 inhibitor abemaciclib with xentuzumab, a humanized IGF-1 and IGF-2 ligand co-neutralizing monoclonal antibody, results in synergistic antineoplastic effects in human breast cancer cell lines

Cancer research (Chicago, Ill.), 2018-07, Vol.78 (13_Supplement), p.1852-1852

2018

Link zum Volltext

Verfügbarkeit prüfen

Abstract 2836: Characterization of the mechanism of action for abemaciclib with antiestrogen combined therapy in human breast cancer cell lines

Cancer research (Chicago, Ill.), 2016-07, Vol.76 (14_Supplement), p.2836-2836

2016

Link zum Volltext

Verfügbarkeit prüfen

Abstract 3101: In-vitro characterization of Abemaciclib pharmacology in ER+ breast cancer cell lines

Cancer research (Chicago, Ill.), 2015-08, Vol.75 (15_Supplement), p.3101-3101

2015

Link zum Volltext

Verfügbarkeit prüfen

Abstract 2818: An unbiased tumor cell panel profiling method to identify drug-drug interactions reveals synergy between the CDK4 and CDK 6 inhibitor abemaciclib and the Raf dimer and pan-Raf inhibitor LY3009120 in Ras mutant cancers

Cancer research (Chicago, Ill.), 2016-07, Vol.76 (14_Supplement), p.2818-2818

2016

Link zum Volltext

Verfügbarkeit prüfen

Abstract A07: The identification of combinations for the CDK4 and CDK6 inhibitor, abemaciclib

Molecular cancer research, 2016-11, Vol.14 (11_Supplement), p.A07-A07

2016

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 47

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(40)
Mit Volltextzugriff
(47)

Publikationsform

Sprache

Englisch
(47)
Japanisch
(5)

Erscheinungsjahr

n.n

Thema

Science & Technology
(27)
Life Sciences & Biomedicine
(24)
Humans
(11)
Animals
(10)
Biochemistry & Molecular Biology
(10)
Cell Biology
(9)
Oncology
(9)
Cell Cycle
(8)
Physical Sciences
(7)
Chemistry
(6)
Antineoplastic Agents - Pharmacology
(5)
Exons
(4)
Pharmacology & Pharmacy
(4)
Alternative Splicing
(3)
Aminopyridines - Pharmacology
(3)
Antineoplastic Agents - Therapeutic Use
(3)
Benzimidazoles - Pharmacology
(3)
Cell Line
(3)
Cell Nucleus - Metabolism
(3)
Chemistry, Medicinal
(3)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Preclinical characterization of abemaciclib in hormone receptor positive breast cancer

Assay Establishment and Validation of a High-Throughput Screening Platform for Three-Dimensional Patient-Derived Colon Cancer Organoid Cultures

TPX2 overexpression promotes sensitivity to dasatinib in breast cancer by activating YAP transcriptional signaling

Cyclin dependent kinase (CDK) inhibitors as anticancer drugs

Phenotypic Screening Approaches to Develop Aurora Kinase Inhibitors: Drug Discovery Perspectives

Preclinical characterization of the CDK4/6 inhibitor LY2835219: in-vivo cell cycle-dependent/independent anti-tumor activities alone/in combination with gemcitabine

Genomic Aberrations that Activate D-type Cyclins Are Associated with Enhanced Sensitivity to the CDK4 and CDK6 Inhibitor Abemaciclib

Multiparametric cell-based assay for the evaluation of transcription inhibition by high-content imaging

Aurora A Kinase Inhibition Is Synthetic Lethal with Loss of the RB1 Tumor Suppressor Gene

Design, synthesis and validation of a new Crimped Head-Piece for DNA-Encoded libraries generation

Aurora A-Selective Inhibitor LY3295668 Leads to Dominant Mitotic Arrest, Apoptosis in Cancer Cells, and Shows Potent Preclinical Antitumor Efficacy

Crystal structure of active CDK4-cyclin D and mechanistic basis for abemaciclib efficacy

The interaction of p62 with RIP links the atypical PKCs to NF-κB activation

Activation of IκB Kinase β by Protein Kinase C Isoforms

Author Correction: Crystal structure of active CDK4-cyclin D and mechanistic basis for abemaciclib efficacy

Cyclin dependent kinase (CDK) inhibitors as anticancer drugs: Recent advances (2015–2019)

Abemaciclib, a CDK4 and 6 inhibitor with unique pharmacological properties for breast cancer therapy

Abstract 1236: Preclinical characterization of LY3484356, a novel, potent and orally bioavailable selective estrogen receptor degrader (SERD)

Splicing Regulation at the Second Catalytic Step by Sex-lethal Involves 3′ Splice Site Recognition by SPF45

Abstract 1852: Combination of the CDK4/6 inhibitor abemaciclib with xentuzumab, a humanized IGF-1 and IGF-2 ligand co-neutralizing monoclonal antibody, results in synergistic antineoplastic effects in human breast cancer cell lines

Abstract 2836: Characterization of the mechanism of action for abemaciclib with antiestrogen combined therapy in human breast cancer cell lines

Abstract 3101: In-vitro characterization of Abemaciclib pharmacology in ER+ breast cancer cell lines

Abstract 2818: An unbiased tumor cell panel profiling method to identify drug-drug interactions reveals synergy between the CDK4 and CDK 6 inhibitor abemaciclib and the Raf dimer and pan-Raf inhibitor LY3009120 in Ras mutant cancers

Abstract P4-08-02: LOXO-783: A potent, highly mutant selective and brain-penetrant allosteric PI3Kα H1047R inhibitor in combination with standard of care (SOC) treatments in preclinical PI3Kα H1047R-mutant breast cancer models

Abstract A07: The identification of combinations for the CDK4 and CDK6 inhibitor, abemaciclib

Suchergebnisse filtern